Economic implications of treatment guidelines for congestive heart failure.

Economic implications of treatment guidelines for congestive heart failure. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Economic implications of treatment guidelines for congestive heart failure. Abstract Text:

Marcelo C Shibata,Carolyn Nilsson,Marilou Hervas-Malo,Philip Jacobs,Ross T Tsuyuki,

Congestive heart failure (CHF) is the most common cause of cardiovascular hospital admission. A significant proportion of the costs of CHF is due to hospitalizations. The present study evaluated the economic impact of a modest increase in the use of angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, spironolactone and digoxin on CHF hospitalizations. Patients with CHF were identified through the Canadian Institute for Health Information (CIHI) database. The efficacy of ACE inhibitors, beta-blockers, spironolactone and digoxin in the first year of treatment were retrieved from the Survival and Ventricular Enlargement (SAVE) trial, a meta-analysis, the Randomized Aldactone Evaluation Study (RALES) and the Digitalis Investigation Group (DIG) trial, respectively. Cost of CHF hospitalization was based on the National List of Provincial Costs. Costs of drug treatment were based on the 2002 Alberta Health and Wellness Drug Benefit list. Physician visits for drug titration were also included in the model. A total of 85,679 patients with CHF were identified with a total of 106,130 hospital discharges. A 10% increase in use of ACE inhibitors, beta-blockers, spironolactone and digoxin would incur in a total cost due to avoidable hospital admissions of 0.4 million dollars, 1.3 million dollars, 3.7 million dollars and 1.2 million dollars, respectively. Similarly, the costs of drug treatment would be 2.2 million dollars, 1.3 million dollars, 0.3 million dollars and 0.5 million dollars, respectively. An increase in the use of the above medications would save 6.6 million dollars due to avoidable hospital admissions. The total cost of drug treatment was 4.3 million dollars, giving a net savings of 2.3 million dollars in the first year. The implementation of evidence-based therapy for CHF treatment is not only clinically efficacious, but also economically attractive.

Economic implications of treatment guidelines for congestive heart failure. Publishing Authors By Initials

MC Shibata,C Nilsson,M Hervas-Malo,P Jacobs,RT Tsuyuki,

For similar organic chemicals: lactones: spironolactone research abstracts see: organic chemicals: lactones: spironolactone research

PUBMED ID PMID:

MEDLINE DATE:

Economic implications of treatment guidelines for congestive heart failure. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The Canadian journal of cardiology

VOLUME: 21

Page Numbers: 1301-6

Journal Abbreviation:

ISSN: 1916-7075

DAY: 3

MONTH: Dec

YEAR: 2005

Economic implications of treatment guidelines for congestive heart failure. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8510280

Economic implications of treatment guidelines for congestive heart failure. Keywords Mesh Terms:

KEYWORDS: Spironolactone

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Economic implications of treatment guidelines for congestive heart failure. Information

Substance Name: Spironolactone

Registry Number: 52-01-7

Grant and Affiliation Information for Economic implications of treatment guidelines for congestive heart failure.

AFFILIATION: University of Alberta, Edmonton.

Country: Canada

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Can J Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Economic implications of treatment guidelines for congestive heart failure Related Publications

• Automatic Selection of Optimal Cardiac-phase in Coronary CT Angiography-Its Clinical Usefulness for Patients with Atrial Fibrillation.
• Economic implications of treatment guidelines for congestive heart failure.
• Levels of evidence in cardiovascular clinical practice guidelines.
• Patient preferences for ongoing warfarin management after receiving care by an anticoagulation management service.
• Pharmacist care of patients with heart failure: a systematic review of randomized trials.
• The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation.
• Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies.
• Women's Recovery from Sternotomy-Extension (WREST-E) study: examining long-term pain and discomfort following sternotomy and their predictors.